Check-Cap Ltd. (CHEK): Price and Financial Metrics
CHEK Price/Volume Stats
| Current price | $1.78 | 52-week high | $9.20 |
| Prev. close | $1.55 | 52-week low | $1.22 |
| Day low | $1.56 | Volume | 72,000 |
| Day high | $1.78 | Avg. volume | 61,383 |
| 50-day MA | $1.42 | Dividend yield | N/A |
| 200-day MA | $3.59 | Market Cap | 8.58M |
CHEK Stock Price Chart Interactive Chart >
Check-Cap Ltd. (CHEK) Company Bio
Check-Cap Ltd. is a clinical stage medical diagnostics company engaging in the development of ingestible imaging capsule system for colorectal cancer screening. The company was founded by Yoav Kimchy in April 2005 and is headquartered in Isfiya, Israel.
Latest CHEK News From Around the Web
Below are the latest news stories about CHECK-CAP LTD that investors may wish to consider to help them evaluate CHEK as an investment opportunity.
Check-Cap Reports Fourth Quarter and Full Year 2022 Financial ResultsCheck-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced financial results for the fourth quarter and full year ended December 31, 2022. |
Why Are Check-Cap Shares Plummeting Today?Following an internal assessment of the clinical data collected from calibration studies, Check-Cap Ltd (NASDAQ: CHEK) said the current efficacy results do not meet the goal to proceed to the powered portion of the U.S. pivotal study. The company initiated the first part of the pivotal U.S. study of C-Scan in May 2022, focusing on device calibration and enhancement of C-Scan algorithms among the average-risk U.S. population. Check-Cap said the calibration studies’ target is to optimize the C-Sca |
Check-Cap Issues an Update to ShareholdersCheck-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly bowel prep-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today issued the following letter from its chief executive officer, Alex Ovadia, to its shareholders and the investment community: |
Check-Cap Reports Third Quarter 2022 Financial Results and Provides a Corporate UpdateCheck-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced financial results and provided a corporate update for the third quarter and nine months ended September 30, 2022. |
Check-Cap Reports Second Quarter 2022 Financial Results and Provides a Corporate UpdateCheck-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced financial results and provided a corporate update for the second quarter and six months ended June 30, 2022. |
CHEK Price Returns
| 1-mo | 28.06% |
| 3-mo | -46.39% |
| 6-mo | -50.69% |
| 1-year | -75.77% |
| 3-year | -84.52% |
| 5-year | -97.98% |
| YTD | -19.09% |
| 2022 | -83.70% |
| 2021 | 46.67% |
| 2020 | -73.26% |
| 2019 | -20.00% |
| 2018 | -79.41% |
Loading social stream, please wait...